Literature DB >> 11756758

The clinicopathologic spectrum and management of nonalcoholic fatty liver disease.

Melissa J Contos1, Arun J Sanyal.   

Abstract

Nonalcoholic fatty liver disease (NAFD) comprises a spectrum of conditions characterized by the presence of predominantly macrovesicular fatty change in the liver and the absence of alcohol consumption in amounts considered detrimental to the liver. The histologic spectrum of NAFLD includes fatty liver alone or steatohepatitis (NASH). Nonalcoholic steatohepatitis is associated with increasing fibrosis is some cases and may progress to cirrhosis. Nonalcoholic fatty liver disease is often associated with insulin resistance. It is likely that there are one or more additional pathophysiologic defects in those with NASH, rendering them more susceptible to injury from oxidative stress. The clinical and histologic features of NASH are described, and an approach to the diagnosis and treatment of NAFLD is provided.

Entities:  

Mesh:

Year:  2002        PMID: 11756758     DOI: 10.1097/00125480-200201000-00005

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  19 in total

1.  Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis.

Authors:  Waleed M Alazmi; Arie Regev; Enrique G Molina; Eugene R Schiff
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

2.  Non-alcoholic fatty liver disease in patients with HCV genotype 4.

Authors:  A El-Zayadi; M Attia; E M F Barakat; K Zalata; A Saeid; H Hamdy; A El-Nakeeb
Journal:  Gut       Date:  2007-03-13       Impact factor: 23.059

3.  Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3).

Authors:  Jeffrey A Handy; Neeraj K Saxena; Pingping Fu; Songbai Lin; Jamie E Mells; Nitika A Gupta; Frank A Anania
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

4.  A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies.

Authors:  Mariana Catta-Preta; Leonardo Souza Mendonca; Julio Fraulob-Aquino; Marcia Barbosa Aguila; Carlos Alberto Mandarim-de-Lacerda
Journal:  Virchows Arch       Date:  2011-09-08       Impact factor: 4.064

5.  The plasma lipidomic signature of nonalcoholic steatohepatitis.

Authors:  Puneet Puri; Michelle M Wiest; Onpan Cheung; Faridoddin Mirshahi; Carol Sargeant; Hae-Ki Min; Melissa J Contos; Richard K Sterling; Michael Fuchs; Huiping Zhou; Steven M Watkins; Arun J Sanyal
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

6.  In vivo hepatic lipid quantification using MRS at 7 Tesla in a mouse model of glycogen storage disease type 1a.

Authors:  Nirilanto Ramamonjisoa; Helene Ratiney; Elodie Mutel; Herve Guillou; Gilles Mithieux; Frank Pilleul; Fabienne Rajas; Olivier Beuf; Sophie Cavassila
Journal:  J Lipid Res       Date:  2013-04-17       Impact factor: 5.922

7.  Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Richard K Sterling; Melissa J Contos; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Mitchell L Shiffman; Arun J Sanyal
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

Review 8.  Nonalcoholic fatty liver disease as a component of the metabolic syndrome.

Authors:  Mouen A Khashab; Suthat Liangpunsakul; Naga Chalasani
Journal:  Curr Gastroenterol Rep       Date:  2008-02

9.  Hepatitis C comorbidities affecting the course and response to therapy.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

10.  Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation.

Authors:  Neeraj K Saxena; Mark A Titus; Xiaokun Ding; Jeffrey Floyd; Shanthi Srinivasan; Shanthi V Sitaraman; Frank A Anania
Journal:  FASEB J       Date:  2004-08-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.